Development of a novel vaccine delivery system based on Gantrez nanoparticles.
The adjuvant capacity of a novel vaccine vector “Gantrez-nanoparticles” (NP) towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles were prepared by a solvent displacement method previously described. The protein was incorporated during the manufacturing process (OVA-e...
| Main Authors: | , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
American Scientific Publishers
2011
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/17367 |
| _version_ | 1793400029755473920 |
|---|---|
| author | Gomez, S. (Sara) Gamazo, C. (Carlos) San-Roman, B. (Beatriz) Vauthier, C. (Christine) Ferrer-Cardona, M. (Marta) Irache, J.M. (Juan Manuel) |
| author_facet | Gomez, S. (Sara) Gamazo, C. (Carlos) San-Roman, B. (Beatriz) Vauthier, C. (Christine) Ferrer-Cardona, M. (Marta) Irache, J.M. (Juan Manuel) |
| author_sort | Gomez, S. (Sara) |
| collection | DSpace |
| description | The adjuvant capacity of a novel vaccine vector “Gantrez-nanoparticles” (NP)
towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles
were prepared by a solvent displacement method previously described. The protein was
incorporated during the manufacturing process (OVA-encapsulated nanoparticles) or
after the preparation (OVA-coated nanoparticles). The mean size of the different
nanoparticle formulations was lower than 300 nm, and the OVA content ranged
approximately from 67 μg/mg nanoparticles (for OVA-coated nanoparticles) to 30
μg/mg nanoparticles (for OVA-encapsulated nanoparticles). All the OVA-NP
formulations were capable of amplifying the antibodies titres (IgG1 and IgG2a) in mice
after a single subcutaneous inoculation with respect free OVA or OVA adsorbed to
Alum. Furthermore, the elicited response was, for some formulations, predominantly
Th1 subtype. Thus, the formulation that contained mainly the antigen inside, and with a
low concentration of cross-linking agent, displayed the best potential to induce a Th1
response after 35 days post-immunisation. These results are highly suggestive for the
use of Gantrez nanoparticles as an efficient antigen delivery system, especially when a
long lasting Th1 cytokine response is required. |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-17367 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2011 |
| publisher | American Scientific Publishers |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-173672024-02-07T11:35:22Z Development of a novel vaccine delivery system based on Gantrez nanoparticles. Gomez, S. (Sara) Gamazo, C. (Carlos) San-Roman, B. (Beatriz) Vauthier, C. (Christine) Ferrer-Cardona, M. (Marta) Irache, J.M. (Juan Manuel) Gantrez Nanoparticles Adjuvant Vacine-carrier The adjuvant capacity of a novel vaccine vector “Gantrez-nanoparticles” (NP) towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles were prepared by a solvent displacement method previously described. The protein was incorporated during the manufacturing process (OVA-encapsulated nanoparticles) or after the preparation (OVA-coated nanoparticles). The mean size of the different nanoparticle formulations was lower than 300 nm, and the OVA content ranged approximately from 67 μg/mg nanoparticles (for OVA-coated nanoparticles) to 30 μg/mg nanoparticles (for OVA-encapsulated nanoparticles). All the OVA-NP formulations were capable of amplifying the antibodies titres (IgG1 and IgG2a) in mice after a single subcutaneous inoculation with respect free OVA or OVA adsorbed to Alum. Furthermore, the elicited response was, for some formulations, predominantly Th1 subtype. Thus, the formulation that contained mainly the antigen inside, and with a low concentration of cross-linking agent, displayed the best potential to induce a Th1 response after 35 days post-immunisation. These results are highly suggestive for the use of Gantrez nanoparticles as an efficient antigen delivery system, especially when a long lasting Th1 cytokine response is required. 2011-03-30T15:52:54Z 2011-03-30T15:52:54Z 2006 info:eu-repo/semantics/article https://hdl.handle.net/10171/17367 eng info:eu-repo/semantics/openAccess application/pdf American Scientific Publishers |
| spellingShingle | Gantrez Nanoparticles Adjuvant Vacine-carrier Gomez, S. (Sara) Gamazo, C. (Carlos) San-Roman, B. (Beatriz) Vauthier, C. (Christine) Ferrer-Cardona, M. (Marta) Irache, J.M. (Juan Manuel) Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title | Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title_full | Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title_fullStr | Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title_full_unstemmed | Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title_short | Development of a novel vaccine delivery system based on Gantrez nanoparticles. |
| title_sort | development of a novel vaccine delivery system based on gantrez nanoparticles. |
| topic | Gantrez Nanoparticles Adjuvant Vacine-carrier |
| url | https://hdl.handle.net/10171/17367 |
| work_keys_str_mv | AT gomezssara developmentofanovelvaccinedeliverysystembasedongantreznanoparticles AT gamazoccarlos developmentofanovelvaccinedeliverysystembasedongantreznanoparticles AT sanromanbbeatriz developmentofanovelvaccinedeliverysystembasedongantreznanoparticles AT vauthiercchristine developmentofanovelvaccinedeliverysystembasedongantreznanoparticles AT ferrercardonammarta developmentofanovelvaccinedeliverysystembasedongantreznanoparticles AT irachejmjuanmanuel developmentofanovelvaccinedeliverysystembasedongantreznanoparticles |